ArticleInternational journal of nanomedicine2026
Thermoradiotherapy-Driven Enhancement of Cuproptosis by Copper-Nitroimidazole Based Nanoparticles.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cuproptosis, a novel form of cell death tied to copper homeostasis and protein lipoylation, holds significant promise for breast cancer treatment. However, its efficacy is severely hindered by the tumor microenvironment (TME) heterogeneity, such as hypoxia and elevated glutathione (GSH) levels. Methods: Herein, we synthesized CuNI nanoparticles via a facile hydrothermal method, which could serve as both a copper carrier and a photothermal agent, to enhance the accumulation of copper in tumor site. Following intravenous injection, CuNI accumulated and persisted in tumors via the enhanced permeability and retention effect (EPR) effect. Subsequent gradient 808 nm laser irradiation and radiotherapy (RT) were administered, CuNI could convert light energy to heat energy, which could alleviate hypoxia TME, while RT further depleted GSH and synergistically generates reactive oxygen species (ROS) with CuNI, synergistically amplifying CuNi-mediated cuproptosis. Results: This co-treatment triggered immunogenic cell death (ICD), activating dendritic cells and T-cell responses to reverse the "cold" immune microenvironment. In vivo studies demonstrated complete tumor suppression with no overt toxicity. Conclusion: The CuNI + NIR + RT strategy, leveraging "cuproptosis/ICD synergy", offers a novel paradigm for the clinical translation of cuproptosis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.